8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A deep methodological critique of the SELECT trial (semaglutide 2.4 mg, NEJM 2023): enrollment biases, follow-up gaps, statistical caveats, COI concerns, and what post-publication commentary revealed.
A deep-dive into the SELECT trial's randomization, blinding, endpoint adjudication, estimand framework, and statistical design that shaped the landmark 20% MACE reduction with semaglutide 2.4 mg.
A deep-dive into the health-economic evidence from the SELECT trial: cost-per-QALY estimates, payer-coverage dynamics, list-price vs net-price reality, and how individual patients can weigh the relative value of semaglutide 2.4 mg for cardiovascular risk reduction.
What the SELECT trial's follow-up and extension analyses reveal about the durability of semaglutide 2.4 mg's cardiovascular benefits, long-term safety signals, and unanswered questions beyond the primary endpoint.
A deep-dive into the SELECT trial's primary and secondary endpoint results for semaglutide 2.4 mg, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
Deep dive into the SELECT trial's pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg, examining differential MACE reduction by age, sex, BMI, race, and baseline biomarkers in patients with overweight/obesity and established cardiovascular disease.
A plain-English deep dive into the SELECT trial, the landmark RCT that proved semaglutide 2.4 mg reduces heart attacks and strokes in people with obesity and existing cardiovascular disease, even without diabetes.
How the SELECT trial's 20% MACE reduction with semaglutide 2.4 mg reshapes prescribing for patients with obesity and established cardiovascular disease, even without diabetes.